Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| GeoVax Labs, Inc.GOVX · Entity 8419 | Chief Scientific Officer | December 17, 2018 | December 19, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
GeoVax Labs, Inc.
Report date December 17, 2018 · Filed December 19, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock Purchase OptionSEC Table II · derivative / convertible security · Conversion / exercise price $0.03 · Expires 2028-12-17 | Direct | 625,000 |
Reported balance
After 2018-12-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-12-17 · Grant · Acquired 625,000 · Balance 625,000 F1: Stock option becomes exercisable in three equal annual installments of the first three anniversary dates of the grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Stock option becomes exercisable in three equal annual installments of the first three anniversary dates of the grant.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Vaxxinity, Inc.
Report date January 13, 2022 · Filed August 29, 2022
Section 16 reporting ended · disclosed 2022-08-29. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A common stockSEC Table I · non-derivative | Direct | 10,000 |
Reported balance
After 2022-01-13 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2022-01-13 · Exercise / conversion · Acquired 10,000 · Balance 10,000 |
| Class A common stockSEC Table I · non-derivative | Direct | 40,000 |
Reported balance
After 2022-07-29 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2022-07-29 · Exercise / conversion · Acquired 20,000 · Balance 40,000 F1: The Reporting Person's Form 4 filed on May 5, 2022 incorrectly reported that the Reporting Person owned 10,000 shares of Class A common stock after the transaction on May 3, 2022 but the Reporting Person then owned 20,000 shares of Class A common stock. |
| Class A common stockSEC Table I · non-derivative | Direct | 66,005 |
Reported balance
After 2022-08-15 transaction · row 3
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 3 · 2022-08-15 · Exercise / conversion · Acquired 26,005 · Balance 66,005 |
| Class A common stockSEC Table I · non-derivative | Direct | 68,645 |
Reported balance
After 2022-08-22 transaction · row 4
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 4 · 2022-08-22 · Exercise / conversion · Acquired 2,640 · Balance 68,645 |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.57 · Expires 2031-03-01 | Direct | 116,730 |
Reported balance
After 2022-01-13 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2022-01-13 · Exercise / conversion · Disposed 10,000 · Balance 116,730 F2: These options are subject to a four year time-based vesting schedule, with 25% vested on 6/5/2021 and the remainder vesting in equal installments each month during the remainder of the vesting period. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.57 · Expires 2031-03-01 | Direct | 86,730 |
Reported balance
After 2022-07-29 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2022-07-29 · Exercise / conversion · Disposed 20,000 · Balance 86,730 F2: These options are subject to a four year time-based vesting schedule, with 25% vested on 6/5/2021 and the remainder vesting in equal installments each month during the remainder of the vesting period. F3: The Reporting Person's Form 4 filed on May 5, 2022 incorrectly reported that the Reporting Person owned 116,730 of these stock options after the transaction on May 3, 2022 but the Reporting Person then owned 106,730 of these stock options. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.57 · Expires 2031-03-01 | Direct | 60,725 |
Reported balance
After 2022-08-15 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2022-08-15 · Exercise / conversion · Disposed 26,005 · Balance 60,725 F2: These options are subject to a four year time-based vesting schedule, with 25% vested on 6/5/2021 and the remainder vesting in equal installments each month during the remainder of the vesting period. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.57 · Expires 2031-03-01 | Direct | 58,085 |
Reported balance
After 2022-08-22 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2022-08-22 · Exercise / conversion · Disposed 2,640 · Balance 58,085 F2: These options are subject to a four year time-based vesting schedule, with 25% vested on 6/5/2021 and the remainder vesting in equal installments each month during the remainder of the vesting period. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person's Form 4 filed on May 5, 2022 incorrectly reported that the Reporting Person owned 10,000 shares of Class A common stock after the transaction on May 3, 2022 but the Reporting Person then owned 20,000 shares of Class A common stock.
F2: These options are subject to a four year time-based vesting schedule, with 25% vested on 6/5/2021 and the remainder vesting in equal installments each month during the remainder of the vesting period.
F3: The Reporting Person's Form 4 filed on May 5, 2022 incorrectly reported that the Reporting Person owned 116,730 of these stock options after the transaction on May 3, 2022 but the Reporting Person then owned 106,730 of these stock options.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 22, 2022 Filed Aug 29, 2022 16:45 UTC | Vaxxinity, Inc. VAXX · Entity 91688 | Exercise / conversionStock option (right to buy) · Derivative | 2,640 | $0.00 Strike: $0.57 | $0.00 |
DisclosureSEC source: 0001437749-22-021457 · rdgdoc.xml · derivative · entry 8 Guirakhoo Farshad · CIK 0001656602 · (Former) Chief Scientific Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,085 Underlying: Class A common stock · 2,640 shares Expires 2031-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: These options are subject to a four year time-based vesting schedule, with 25% vested on 6/5/2021 and the remainder vesting in equal installments each month during the remainder of the vesting period. Read SEC document |
| August 22, 2022 Filed Aug 29, 2022 16:45 UTC | Vaxxinity, Inc. VAXX · Entity 91688 | Exercise / conversionClass A common stock | 2,640 | $0.57 | $1,504.80 |
DisclosureSEC source: 0001437749-22-021457 · rdgdoc.xml · nonDerivative · entry 4 Guirakhoo Farshad · CIK 0001656602 · (Former) Chief Scientific Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,645 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 15, 2022 Filed Aug 29, 2022 16:45 UTC | Vaxxinity, Inc. VAXX · Entity 91688 | Exercise / conversionStock option (right to buy) · Derivative | 26,005 | $0.00 Strike: $0.57 | $0.00 |
DisclosureSEC source: 0001437749-22-021457 · rdgdoc.xml · derivative · entry 7 Guirakhoo Farshad · CIK 0001656602 · (Former) Chief Scientific Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,725 Underlying: Class A common stock · 26,005 shares Expires 2031-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: These options are subject to a four year time-based vesting schedule, with 25% vested on 6/5/2021 and the remainder vesting in equal installments each month during the remainder of the vesting period. Read SEC document |
| August 15, 2022 Filed Aug 29, 2022 16:45 UTC | Vaxxinity, Inc. VAXX · Entity 91688 | Exercise / conversionClass A common stock | 26,005 | $0.57 | $14,822.85 |
DisclosureSEC source: 0001437749-22-021457 · rdgdoc.xml · nonDerivative · entry 3 Guirakhoo Farshad · CIK 0001656602 · (Former) Chief Scientific Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,005 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 29, 2022 Filed Aug 29, 2022 16:45 UTC | Vaxxinity, Inc. VAXX · Entity 91688 | Exercise / conversionStock option (right to buy) · Derivative | 20,000 | $0.00 Strike: $0.57 | $0.00 |
DisclosureSEC source: 0001437749-22-021457 · rdgdoc.xml · derivative · entry 6 Guirakhoo Farshad · CIK 0001656602 · (Former) Chief Scientific Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,730 Underlying: Class A common stock · 20,000 shares Expires 2031-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: These options are subject to a four year time-based vesting schedule, with 25% vested on 6/5/2021 and the remainder vesting in equal installments each month during the remainder of the vesting period. F3 · balance_after: The Reporting Person's Form 4 filed on May 5, 2022 incorrectly reported that the Reporting Person owned 116,730 of these stock options after the transaction on May 3, 2022 but the Reporting Person then owned 106,730 of these stock options. Read SEC document |
| July 29, 2022 Filed Aug 29, 2022 16:45 UTC | Vaxxinity, Inc. VAXX · Entity 91688 | Exercise / conversionClass A common stock | 20,000 | $0.57 | $11,400.00 |
DisclosureSEC source: 0001437749-22-021457 · rdgdoc.xml · nonDerivative · entry 2 Guirakhoo Farshad · CIK 0001656602 · (Former) Chief Scientific Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: The Reporting Person's Form 4 filed on May 5, 2022 incorrectly reported that the Reporting Person owned 10,000 shares of Class A common stock after the transaction on May 3, 2022 but the Reporting Person then owned 20,000 shares of Class A common stock. Read SEC document |
| May 03, 2022 Filed May 5, 2022 13:39 UTC | Vaxxinity, Inc. VAXX · Entity 91688 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $0.57 | $0.00 |
DisclosureSEC source: 0000899243-22-016779 · doc4.xml · derivative · entry 2 Guirakhoo Farshad · CIK 0001656602 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,730 Underlying: Class A common stock · 10,000 shares Expires 2031-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: These options are subject to a four year time-based vesting schedule, with 25% vested on 6/5/2021 and the remainder vesting in equal installments each month during the remainder of the vesting period. Read SEC document |
| May 03, 2022 Filed May 5, 2022 13:39 UTC | Vaxxinity, Inc. VAXX · Entity 91688 | Exercise / conversionClass A common stock | 10,000 | $0.57 | $5,700.00 |
DisclosureSEC source: 0000899243-22-016779 · doc4.xml · nonDerivative · entry 1 Guirakhoo Farshad · CIK 0001656602 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 13, 2022 Filed Aug 29, 2022 16:45 UTC | Vaxxinity, Inc. VAXX · Entity 91688 | Exercise / conversionStock option (right to buy) · Derivative | 10,000 | $0.00 Strike: $0.57 | $0.00 |
DisclosureSEC source: 0001437749-22-021457 · rdgdoc.xml · derivative · entry 5 Guirakhoo Farshad · CIK 0001656602 · (Former) Chief Scientific Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,730 Underlying: Class A common stock · 10,000 shares Expires 2031-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: These options are subject to a four year time-based vesting schedule, with 25% vested on 6/5/2021 and the remainder vesting in equal installments each month during the remainder of the vesting period. Read SEC document |
| January 13, 2022 Filed Aug 29, 2022 16:45 UTC | Vaxxinity, Inc. VAXX · Entity 91688 | Exercise / conversionClass A common stock | 10,000 | $0.57 | $5,700.00 |
DisclosureSEC source: 0001437749-22-021457 · rdgdoc.xml · nonDerivative · entry 1 Guirakhoo Farshad · CIK 0001656602 · (Former) Chief Scientific Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 11, 2021 Filed Nov 15, 2021 18:50 UTC | Vaxxinity, Inc. VAXX · Entity 91688 | GrantStock option (right to buy) · Derivative | 41,958 | $0.00 Strike: $13.00 | $0.00 |
DisclosureSEC source: 0000899243-21-044646 · doc4.xml · derivative · entry 1 Guirakhoo Farshad · CIK 0001656602 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,958 Underlying: Class A common stock · 41,958 shares Expires 2031-11-11 F1 · derivative.exercise_date: These options are subject to a four-year time-vesting schedule, with 25% vesting on the first anniversary of the grant date] and the remainder vesting in equal installments each month during the remainder of the vesting period. Read SEC document |
| December 17, 2018 Filed Dec 19, 2018 20:31 UTC | GeoVax Labs, Inc. GOVX · Entity 8419 | GrantCommon Stock Purchase Option · Derivative | 625,000 | $0.00 Strike: $0.03 | $0.00 |
DisclosureSEC source: 0001437749-18-022291 · rdgdoc.xml · derivative · entry 1 Guirakhoo Farshad · CIK 0001656602 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 625,000 Underlying: Common Stock · 625,000 shares Expires 2028-12-17 F1 · derivative.exercise_date: Stock option becomes exercisable in three equal annual installments of the first three anniversary dates of the grant. Read SEC document |
| December 20, 2017 Filed Dec 22, 2017 16:24 UTC | GeoVax Labs, Inc. GOVX · Entity 8419 | GrantCommon Stock Purchase Option · Derivative | 500,000 | $0.00 Strike: $0.05 | $0.00 |
DisclosureSEC source: 0001437749-17-021096 · rdgdoc.xml · derivative · entry 1 Guirakhoo Farshad · CIK 0001656602 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2027-12-20 F1 · derivative.exercise_date: Stock option becomes exercisable in three equal annual installments of the first three anniversary dates of the grant. Read SEC document |
| December 13, 2016 Filed Dec 15, 2016 21:27 UTC | GeoVax Labs, Inc. GOVX · Entity 8419 | GrantCommon Stock Purchase Option · Derivative | 85,000 | $0.00 Strike: $0.07 | $0.00 |
DisclosureSEC source: 0001437749-16-043423 · rdgdoc.xml · derivative · entry 1 Guirakhoo Farshad · CIK 0001656602 · Sr VP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,000 Underlying: Common Stock · 85,000 shares Expires 2026-12-13 F1 · derivative.exercise_date: Stock option becomes exercisable in three equal annual installments of the first three anniversary dates of the grant. Read SEC document |
| December 13, 2016 Filed Dec 15, 2016 21:28 UTC | GeoVax Labs, Inc. GOVX · Entity 8419 | GrantCommon Stock Purchase Option · Derivative | 85,000 | $0.00 Strike: $0.07 | $0.00 |
DisclosureSEC source: 0001437749-16-043424 · rdgdoc.xml · derivative · entry 1 Guirakhoo Farshad · CIK 0001656602 · Sr VP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,000 Underlying: Common Stock · 85,000 shares Expires 2026-12-13 F1 · derivative.exercise_date: Stock option becomes exercisable in three equal annual installments of the first three anniversary dates of the grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.